RECORD study designed to evaluate the cardiovascular safety of Avandia
What’s the problem?
February 22, 2010 – The FDA is reviewing data from a large, long-term clinical study on the possible risks associated with Avandia. Called the Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycemia in Diabetes or RECORD study, it was designed to evaluate the cardiovascular safety of Avandia.
The FDA is currently reviewing the primary data from the completed RECORD study, and no new conclusions or recommendations about the use of Avandia in the treatment of type 2 diabetes have been made at this time.
Once the FDA completes its review of the data from the study, it will present the safety data on Avandia at a joint public meeting of the Endocrinologic and Metabolic Drugs and Drug Safety and Risk Management Advisory Committees in July 2010. At that meeting, the Advisory Committee will provide an updated assessment of the risks and benefits of Avandia in the treatment of type 2 diabetes.
Contact an Avandia Lawyer
Schmidt & Clark, LLP is currently accepting new Avandia cases throughout the entire United States. Our Defective Drug Litigation Group consists of highly experienced trial lawyers that focus exclusively on the representation of plaintiffs in Avandia lawsuits.
Again, if you or a loved one has been prescribed Avandia and are experiencing side effects, you should contact our law firm immediately by using the form below. You may be entitled to compensation and we can help.